VP7-2022: An ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): A double-blind, randomized, placebo-controlled, phase III trial

• DOI: 10.1016/j.annonc.2022.11.007
• Publication Date: 2022-12-15T17:26:35Z
• Authors: M.R. Mirza; X. Wu; J. Zhu; R. Yin; J. Yang; J. Liu; J. Wang; L. Wu; Z. Liu; Y. Gao; D. Wang; G. Lou; H. Yang; Q. Zhou; B. Kong; Y. Huang; L. Chen; X. Zhen; J. Dong; J. Hou
• Keywords: 03 medical and health sciences; 0302 clinical medicine